drugset / Trial / NCT05241288
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
Completed
54 enrolled
University of North Carolina, Chapel Hill
Teva Branded Pharmaceutical Products R&D, Inc. · collabWake Forest University Health Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics \[peak inspiratory flow (PIF), inhalation volume, number of inhalation events\] amongst COPD patients in the ambulatory setting.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2023-02-13
- Completion
- 2023-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Salbutamol | Unknown | — | Inhaled |